Clinical Trial

Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project

Study acronym: ASCAPE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality of Life (QoL) and health status. Specifically, ASCAPE aims to provide personalized- and AI-based predictions for QoL issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875351.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-05-04; most recent amendment 2024-11-15.
Status change: Recruiting → Active, Not Recruiting 2024-04-09
Trial Details
NCT Number NCT04879563
Lead Sponsor Region Örebro County
Collaborators: UBITECH, ATOS, Siemens Corporation, Corporate Technology, Intrasoft, University of Patras, FORTH - Foundation for Research and Technology Hellas, Sphynx Technology Solutions AG, University of Novi Sad, DFKI - German Research Center for Artificial Intelligence, CareAcross, National and Kapodistrian University of Athens, Fundacio Clinic Barcelona, Arthur's Legal, Fundacion iSYS
Conditions Breast Cancer, Prostate Cancer, Quality of Life, Survivorship, Toxicity
Enrollment 500 participants
Start Date 2021-02-01
Primary Completion 2024-06-30 (estimated)
Study Completion 2025-08-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-19